Key result
Cardiac contractility modulation provided clinical benefit in an older patient with advanced HFrEF due to dilated cardiomyopathy despite optimal medical therapy.
Why the study?
Does cardiac contractility modulation provide clinical benefit in an older patient with advanced HFrEF despite optimal medical therapy?
Case Report (n=1)
Does cardiac contractility modulation provide clinical benefit in an older patient with advanced HFrEF despite optimal medical therapy?
Cardiac contractility modulation may provide clinical benefit in older patients with advanced HFrEF and frequent hospitalizations despite optimal medical therapy.
Cardiac contractility modulation (CCM) is a novel device-based therapy used in patients with HFrEF. CCM therapy is associated with an improvement in exercise tolerance, increased quality of life, reduced HF hospitalizations, and reverse remodelling of the left ventricle in patients with HFrEF. In this case, we report the clinical benefit of CCM in an older patient with advanced HFrEF due to ischemic dilated cardiomyopathy with frequent heart failure-related hospitalizations and poor quality of life despite optimal medical therapy.
No takes yet. Share an insight, caveat, or question.
Manganelli et al. (2021) conducted a case report in Advanced HFrEF due to dilated cardiomyopathy (n=1). Cardiac contractility modulation (CCM) was evaluated on Clinical benefit. Cardiac contractility modulation provided clinical benefit in an older patient with advanced HFrEF due to dilated cardiomyopathy despite optimal medical therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: